Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals

Exclusion Criteria

• •Positive quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) test for SARS-CoV-2 at the time of inclusion.
• •Panel of IgG or IgM antibodies positive for SARS-CoV-2 at the time of inclusion.
• •Development of respiratory symptoms suspicious of SARS-CoV-2 infection during the first 7 days after treatment is initiated, confirmed by qRT-PCR and IgG or IgM antibodies postiver for SARS-CoV-2.
• •History of allergies to any hydroxychloroquine or bromhexine related compound or medication.
• •Use of immunosuppressors for any reason.
• •History of bone marrow transplant.
• •Known glucose-6-phosphate dehydrogenase deficiency.
• •Chronic kidney disease or glomerular filtration \<20ml/min.
• •Use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone).
• •History of long QT syndrome.
• •Electrocardiogram with QTc\>500 msec.
• •Pregnant or breastfeeding personnel.
• •Epilepsy.
• •Known liver disease.
• •Personnel who have received the Covid-19 vaccine
• •Elimination criteria
• •Personnel who decide to leave the study for any reason not related to adverse events.
• •Personnel with incomplete information on the primary outcome (qRT-PCR for SARS-CoV-2).
• •Personnel who are relocated to work in another institution.
• •Personnel who do not wish to participate in the study